Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift® System in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)

NCT04757116 is registered in ClinicalTrials.gov with Olympus Corporation of the Americas as lead sponsor.

NCT NCT04757116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04757116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift® System in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)
Lead sponsor
Olympus Corporation of the Americas
Phase
Not applicable
Overall status
Recruiting
Start date
September 26, 2022
Completion date
May 31, 2030
Enrollment
256 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia (bph)